The Substance Abuse and Mental Health Services Administration yesterday issued guidance for health care and addiction professionals using methadone, naltrexone or buprenorphine to treat patients with opioid use disorder. Mandated by the Comprehensive Addiction and Recovery Act, the guidance offers appropriate prescribing practices and strategies for supporting patients. It also educates patients, families and the general public about the medications. “We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Elinore McCance-Katz, M.D., assistant secretary for mental health and substance use at the Department of Health and Human Services. For an AHA toolkit and other resources to help hospitals and health systems tackle the opioid crisis, visit www.aha.org/opioidtoolkit.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…